-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| New compounds can improve the pathological changes of Alzheimer's disease |
Science and Technology Daily (Reporter Chen Xi) Alzheimer's disease is an important cause of Alzheimer's.
It can cause memory degradation, cognitive impairment and personality changes in patients, and seriously threaten the lifespan and quality of life of the elderly
.
A few days ago, the team of Professor Tao Zhang from the School of Life Sciences of Nankai University and the team of Professor Guo Dongsheng from the School of Chemistry have made new progress in drug research for the treatment of Alzheimer's disease.
Zhang Tao
Experts said that with the deepening of the aging of the population, the number of patients suffering from Alzheimer's disease is on the rise.
However, there are only a few drugs for clinical treatment of Alzheimer's disease, which are far from satisfying the needs of the majority of patients.
Demand
.
Current research believes that amyloid plaques formed by amyloid-β (Aβ) deposition in the brain are the most significant pathological feature and pathogenic mechanism of Alzheimer's disease
.
Therefore, Aβ has become the most important target of drugs for the treatment of Alzheimer's disease
However, the development of a drug that can not only recognize Aβ, but also inhibit and eliminate amyloid plaques is a major challenge for Alzheimer's disease drug development
.
To this end, the research team of Zhang Tao and Guo Dongsheng applied the concept of heteropolyvalent co-assembly to the treatment of Alzheimer’s disease for the first time, and designed a co-assembly composed of cyclodextrin and cyclic aromatic hydrocarbons based on the amino acid sequence of Aβ.
Zhang Tao
The research team found that the co-assembly exhibited a good ability to depolymerize Aβ fibers and prevent nerve cell death
.
Through animal experiments, it was found that the co-assembly can reduce the levels of different forms of Aβ in the brains of Alzheimer's disease model mice, such as plaques, oligomers, and monomers
The industry believes that such a co-assembly will provide an important reference for the development of new drugs for the treatment of Alzheimer's disease
